Axsome beats on EPS, revenue; Alzheimer's agitation Apr 30 PDUFA date

 

Axsome Therapeutics Inc reports fiscal Q4 2025 results with non-GAAP EPS $-0.56 (+64% YoY) and revenue $194.7M (+64% YoY), beats EPS and revenue estimates

• FY revenue $638.5m, +66% YoY, reported by Axsome for fiscal 2025.
• AUVELITY drove growth with FY sales $507.1m, +74% YoY, and prescriptions up 42% YoY.
• Company remains loss-making but narrowing, with FY net loss improving to $183.2m from $287.2m.
• No 2026 revenue guidance provided; management emphasizes continued operating leverage despite doubling the AUVELITY salesforce.
• AUVELITY Alzheimer's agitation sNDA under priority review with April 30 PDUFA date, and launch readiness activities underway.

https://finviz.com/quote.ashx?t=AXSM&p=d